ArticleOpen forum infectious diseases2022
What is the Role of Lateral Flow Immunoassay for the Diagnosis of Melioidosis?
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Current Melioidosis Diagnostic Landscape and Missed Opportunities in Biomarker Development.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Rapid diagnosis of skin and soft tissue melioidosis in children.PLoS neglected tropical diseases · 2026Article
- The epidemiology and clinical features of melioidosis in the Lao PDR: a 21-year prospective hospital-based cohort study.BMC infectious diseases · 2025Article
- Laboratory diagnosis of melioidosis.PLoS neglected tropical diseases · 2025Review
- Melioidosis molecular diagnostics: An update.Virulence · 2025Review
- Synovial Fluid Analysis in Melioidosis: Experiences from the Darwin Prospective Melioidosis Study.Pathogens (Basel, Switzerland) · 2025Article
- Two Decades of Melioidosis in India: A Comprehensive Epidemiological Review.Pathogens (Basel, Switzerland) · 2025Review
- An improved loop mediated isothermal amplification based assay for the rapid identification of genomic DNA ofCurrent research in microbial sciences · 2025Article
- Performance of MALDI-TOF MS, real-time PCR, antigen detection, and automated biochemical testing for the identification ofJournal of clinical microbiology · 2024Article
- The hidden burden of melioidosis in Nepal: a paradigm for the urgent need to implement a simple laboratory algorithm to detectIJID regions · 2024Review
- The Rapid Emergence of HypervirulentTropical medicine and infectious disease · 2024Review
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Development and evaluation of a multiplex serodiagnostic bead assay (BurkPx) for accurate melioidosis diagnosis.PLoS neglected tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Culture of Methods: We summarized the findings from the 8 studies to date of the Active Melioidosis Detect (AMD) LFA and compared these with our results from 232 patients with culture-confirmed melioidosis. We have also optimized the methodology for testing different clinical samples. Results: Sensitivity and specificity for different samples were broadly similar in our study to those published from Thailand, India, Laos, and Malaysia. One hundred thirty of 232 (56%) of our melioidosis patients were positive on 1 or more AMD tests: 27% for serum (rising to 39% in those with bacteremic melioidosis and 68% in those with septic shock), 63% for urine (72% in bacteremic melioidosis and 90% in septic shock), 85% in sputum that was culture positive, and 83% in pus that was culture positive. Heating sputum and pus samples increased sensitivity. Faint false-positive urine bands seen on earlier AMD versions were not seen when retested using the most recent version, AMD-Plus. Conclusions: While the sensitivity of melioidosis LFA is low overall for blood samples, there is potential for use as a rapid diagnostic: testing serum and urine from those with severe sepsis who may have melioidosis and testing sputum and pus samples from clinically relevant scenarios. Prospective studies of patients with sepsis and other clinical presentations resembling melioidosis are required to ascertain if the specificity of AMD-PLUS is adequate to enable diagnosis of melioidosis with a high positive predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.